Title: Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage
hepatocellular carcinoma treated with trans-arterial chemoembolization
Version: 2 Date: 08 May 2022
Reviewer's report:
Dear Authors,
Thank you for your submission. In my opinion, the major limitation of the study is lack
of novelty. Actually, the application of EZ-ALBI score in clinical practice or clinical trials
is limited. I do not think it has much significance since the ALBI score has shown good
performance for patients treated with TACE during the pase several years.
Title: Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage
hepatocellular carcinoma treated with trans-arterial chemoembolization
Version: 2 Date: 08 May 2022
Reviewer's report:
Dear Authors,
Thank you for your submission. In my opinion, the major limitation of the study is lack
of novelty. Actually, the application of EZ-ALBI score in clinical practice or clinical trials
is limited. I do not think it has much significance since the ALBI score has shown good
performance for patients treated with TACE during the pase several years.
Please review this paper.
user
Title: Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage
hepatocellular carcinoma treated with trans-arterial chemoembolization
Version: 2 Date: 08 May 2022
Reviewer's report:
Dear Authors,
Thank you for your submission. In my opinion, the major limitation of the study is lack
of novelty. Actually, the application of EZ-ALBI score in clinical practice or clinical trials
is limited. I do not think it has much significance since the ALBI score has shown good
performance for patients treated with TACE during the pase several years.
assistant